Summary
60 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 43% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
- It bought back its own shares for 562.2M € in the last fiscal year, 5.4% of its market value.
What to watch
- Revenue grew by only 0.4% a year over the last 3 years.
- It earns only 5.7 EUR a year on every 100 EUR of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 11.1 EUR for 1 EUR of yearly profit. Over the last five years it was 23.8 EUR on average.
Valuation in detailIs it growing?
SlowlyRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 1.9% a year over 5 years. Over the last 3 years it grew by 0.4% a year. For the next fiscal year analysts expect revenue to grow by 0.9%. Earnings per share grew by 43% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 EUR of revenue goes
- Cost of sales 74 EUR
- Research and development 0.8 EUR
- Sales and administration 16 EUR
- Taxes and other 4.9 EUR
- Net profit 4.8 EUR
Net profit, industry median (Medical - Care Facilities) 6.7 EUR
Out of every 100 EUR of revenue, 4.8 EUR is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.2 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, safe- Yield
- 3.97%
- Paid out of profit
- 44%
- Raised in a row
- 2 years
You receive $0.87 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Neutral- Buy 5
- Hold 14
- Sell 2
Today's price within the analysts' price targets
The average target of $23.67 is 7.9% above today's price. 24% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Health Care Services 75%
- Health Care Products 25%
By region
- United States 97%
- Germany 3.4%
Health Care Services brings in 75% of revenue. Health Care Products grew fastest, by 4.3% a year.
Segments in detail